Insider Selling: Cardlytics (NASDAQ:CDLX) CEO Sells $46,844.10 in Stock

Cardlytics, Inc. (NASDAQ:CDLX) CEO Amit Gupta sold 52,049 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $0.90, for a total value of $46,844.10. Following the completion of the sale, the chief executive officer owned 704,803 shares in the company, valued at approximately $634,322.70. The trade was a 6.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Amit Gupta also recently made the following trade(s):

• On Wednesday, February 18th, Amit Gupta sold 45,159 shares of Cardlytics stock. The stock was sold at an average price of $0.93, for a total transaction of $41,997.87.
• On Monday, January 5th, Amit Gupta sold 5,807 shares of Cardlytics stock. The stock was sold at an average price of $1.17, for a total transaction of $6,794.19.

Cardlytics Trading Up 2.4%

Shares of CDLX opened at $0.91 on Friday. Cardlytics, Inc. has a 1-year low of $0.80 and a 1-year high of $3.28. The company has a 50-day moving average of $1.09 and a 200 day moving average of $1.39. The firm has a market capitalization of $49.07 million, a price-to-earnings ratio of -0.43, a PEG ratio of 0.14 and a beta of 1.03. The company has a debt-to-equity ratio of 2.87, a current ratio of 1.14 and a quick ratio of 1.14.

Hedge Funds Weigh In On Cardlytics

Large investors have recently bought and sold shares of the business. Lane Generational LLC increased its holdings in shares of Cardlytics by 28.0% in the 2nd quarter. Lane Generational LLC now owns 780,083 shares of the company’s stock valued at $1,283,000 after acquiring an additional 170,480 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in Cardlytics during the second quarter valued at about $42,000. Brooktree Capital Management grew its stake in Cardlytics by 8.3% in the second quarter. Brooktree Capital Management now owns 242,249 shares of the company’s stock valued at $398,000 after purchasing an additional 18,624 shares during the last quarter. Catalyst Funds Management Pty Ltd bought a new position in Cardlytics in the second quarter worth about $32,000. Finally, XTX Topco Ltd lifted its position in shares of Cardlytics by 143.5% during the second quarter. XTX Topco Ltd now owns 85,971 shares of the company’s stock valued at $141,000 after buying an additional 50,663 shares during the last quarter. Institutional investors own 68.10% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on CDLX. Weiss Ratings reissued a “sell (d-)” rating on shares of Cardlytics in a research note on Monday, December 29th. Wall Street Zen cut Cardlytics from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Three investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Cardlytics currently has an average rating of “Reduce” and a consensus target price of $2.25.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence and marketing platform that connects advertisers with consumers through bank and credit card transaction data. The company partners with financial institutions to analyze anonymized purchase information, enabling brands to deliver highly targeted offers and rewards directly to customers’ online and mobile banking channels. By leveraging real-time insights into consumer spending habits, Cardlytics helps marketers optimize campaign performance and measure return on ad spend more accurately than traditional digital advertising methods.

At the core of Cardlytics’ offering is its proprietary purchase intelligence engine, which aggregates and anonymizes transaction data from partner banks and credit unions.